PTX 203 - Nxera Pharma/PharmEnable
Alternative Names: PTX-203 - Nxera Pharma/PharmEnableLatest Information Update: 05 Aug 2024
Price :
$50 *
At a glance
- Originator Nxera Pharma; PharmEnable
- Class Neuroprotectants; Small molecules
- Mechanism of Action G protein-coupled receptor modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Research Neurological disorders
Most Recent Events
- 24 Jul 2024 Early research in Neurological disorders in Isle of Man(unspecified route) prior to July 2024 (PharmEnable pipeline, July 2024)
- 24 Jul 2024 Early research in Neurological disorders in Japan (unspecified route) prior to July 2024 (PharmEnable pipeline, July 2024)
- 10 Oct 2023 Nxera and PharmEnable collaborate to develop small molecules targeting Neurological disorders